Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GPC-100 · 1 trial · 1 indication
Determine the proportion of patients that will achieve \>=2 x 10\^6 CD34+ cells/kg in 2 leukapheresis sessions following treatment
| Arm | Type | Description |
|---|---|---|
| GPC-100 in combination with propranolol; | EXPERIMENTAL | Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration. Approximately 40 patients will be randomized in a 1:1 ratio to the following treatment arm: • GPC-100 in combination with propranolol; or |
| GPC-100 in combination with propranolol and G-CSF | EXPERIMENTAL | Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration. Approximately 40 patients will be randomized in a 1:1 ratio to the following treatment arm: • GPC-100 in combination with propranolol and G-CSF. |
| Name | Type | Description |
|---|---|---|
| GPC-100 | DRUG | GPC-100 is to be administered at a dose of 3.14 mg/kg GPC-100 free base via IV infusion. The corresponding volume of the reconstituted GPC-100 solution calculated based on the patient weight will be administered via IV infusion over 15 min |
| Propranolol | DRUG | propranolol |
| G-CSF | DRUG | G-CSF |
Inclusion Criteria To be eligible to participate in this study, patients must meet all the following criteria: 1. Male or female, greater than or equal to18 years of age; 2. Patients with diagnosis of MM per the International Myeloma Working Group criteria ; 3. Eligible for ASCT at the Investigato...
Top 20 of 25 competitors
GPC-100 is an investigational small molecule being studied in multiple myeloma. It is being evaluated for its ability to mobilize stem cells in patients with multiple myeloma who are undergoing autologous stem cell transplant. The drug is studied in combination with propranolol, with or without G-CSF.
GPC-100 is being developed by Exicure, Inc., a biopharmaceutical company. Exicure is listed on the stock exchange under the ticker symbol XCUR. The company is conducting clinical research to evaluate the safety and efficacy of GPC-100 in patients with multiple myeloma.
GPC-100 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 2 study of GPC-100 has been completed, and the drug remains under clinical investigation for its potential use in multiple myeloma.
GPC-100 has been studied in a Phase 2 clinical trial registered as NCT05561751. This trial assessed the safety and efficacy of GPC-100 and propranolol, with and without G-CSF, for stem cell mobilization in patients with multiple myeloma undergoing autologous stem cell transplant. The trial was conducted in the United States and enrolled 30 participants.
GPC-100 is a distinct investigational small molecule. It is being studied in combination with propranolol and G-CSF for stem cell mobilization in multiple myeloma. No alternative names for GPC-100 have been reported in the clinical trial information.